Skip to main content

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Avaluació prospectiva de la resposta linfocitària T CD4+ específica pel Virus de l´Hepatitis C (VHC) es receptors de trasplantament hepàtic VHC positiu. Reconstitució de la resposta immune específica

IP: Juan Ignacio Esteban Mur
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Rafael Parra López, Silvia Sauleda Oliveras, Josep Quer Sivila
Funding agency: Fundació La Marató de TV3
Funding: 58388.33
Reference: TV3/002010
Duration: 01/01/2001 - 31/12/2003

Estudio de las variaciones en el grado de estructuración del RNA del VHC en distintos genotipos y en las cuasispecies. Implicaciones en la respuesta al tratamiento con interferon.

IP: Juan Ignacio Esteban Mur
Collaborators: -
Funding agency: Ministerio de Ciencia y Tecnología
Funding: 107653.29
Reference: SAF2000-0183
Duration: 01/11/2000 - 01/11/2003

Virus de l´hepatitis C com factor de risc per desenvolupar una diabetes mellitus: estudi dels mecanismes etiopatogènics

IP: Cristina Hernández Pascual
Collaborators: Rafael Simó Canonge, Juan Ignacio Esteban Mur, Joan Genescà Ferrer
Funding agency: Fundació La Marató de TV3
Funding: 41036.17
Reference: TV3/992610
Duration: 01/01/2000 - 31/12/2002

Related news

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Related professionals

Mª Jesús Cruz Carmona

Mª Jesús Cruz Carmona

Head of group
Pneumology
Read more
Mireia Campius Piñas

Mireia Campius Piñas

Maintenance staff and general services
Ophtalmology
Read more
Màrius Aguirre Canyadell

Màrius Aguirre Canyadell

Senior researcher
Musculoskeletal Tissue Engineering
Read more
Marc Ribó Jacobi

Marc Ribó Jacobi

Main researcher
Stroke research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.